Atossa Therapeutics
ATOS
93 hedge funds and large institutions have $102M invested in Atossa Therapeutics in 2021 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 13 closing their positions.
125% more call options, than puts
Call options by funds: $35M | Put options by funds: $15.6M
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
8% more funds holding
Funds holding: 86 → 93 (+7)
8% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 26
0.34% less ownership
Funds ownership: 1.97% → 1.64% (-0.34%)
55% less capital invested
Capital invested by funds: $226M → $102M (-$124M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.02M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.96M |
| 3 |
D.E. Shaw & Co
New York
|
+$3.48M |
| 4 |
BlackRock
New York
|
+$2.31M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$9.09M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$7.04M |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$6.38M |
| 4 |
Millennium Management
New York
|
-$5.44M |
| 5 |
Jane Street
New York
|
-$4.28M |
ATOS Hedge Fund Activity: Q3 2021 in Review
93 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q3 2021, worth a combined $102M — down 55% from $226M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ATOS positions and 13 closed out — a net gain of 8 holders — while 28 added to existing stakes and 26 trimmed.
The largest buyer was Vanguard Group, adding an estimated $5.02M. The largest seller was Susquehanna International Group, cutting an estimated $9.09M.
- 93 institutional investors held Atossa Therapeutics (ATOS) as of Q3 2021, up from 86 in Q2 2021.
- Funds reported $102M of Atossa Therapeutics stock for Q3 2021, down 55% quarter-over-quarter.
- 21 funds opened new Atossa Therapeutics positions in Q3 2021 and 13 closed out, a net change of +8 holders.
- The largest Atossa Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $5.02M added.
- The largest Atossa Therapeutics seller in Q3 2021 was Susquehanna International Group, an estimated $9.09M sold.
Based on aggregated 13F filings for Q3 2021.